MacroGenics, Merck Seize Gastric Cancer Opportunity With Margetuximab, Keytruda Combo
This article was originally published in Scrip
Executive Summary
MacroGenics Inc. will study the ability of margetuximab to enhance the immune system's destruction of HER2-positive tumors in a Phase Ib/II clinical trial to evaluate the monoclonal antibody in combination with Merck & Co.'s PD-1 inhibitor Keytruda (pembrolizumab) in advanced gastric cancer.